Steven Kridel to Lactones
This is a "connection" page, showing publications Steven Kridel has written about Lactones.
Connection Strength
0.667
-
Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004 Mar 15; 64(6):2070-5.
Score: 0.237
-
Souchek JJ, Davis AL, Hill TK, Holmes MB, Qi B, Singh PK, Kridel SJ, Mohs AM. Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells. . 2017 09; 16(9):1819-1830.
Score: 0.148
-
Hill TK, Davis AL, Wheeler FB, Kelkar SS, Freund EC, Lowther WT, Kridel SJ, Mohs AM. Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines. Mol Pharm. 2016 Mar 07; 13(3):720-8.
Score: 0.135
-
Pemble CW, Johnson LC, Kridel SJ, Lowther WT. Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat. Nat Struct Mol Biol. 2007 Aug; 14(8):704-9.
Score: 0.074
-
Little JL, Wheeler FB, Fels DR, Koumenis C, Kridel SJ. Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res. 2007 Feb 01; 67(3):1262-9.
Score: 0.072